Science.Online
Publisher and Institutes
Akademie Verlag
Deutsches Institut für Urbanistik
Oldenbourg Wissenschaftsverlag
Walter de Gruyter
Schattauer
You are here: Home :: Area NEM :: Medical science :: Human medicine
 
Svitlana Demyanets, Stefan Pfaffenberger, Christoph Kaun, Gersina Rega, Walter S. Speidl, Stefan P. Kastl, Thomas W. Weiss, Philipp J. Hohensinner, Wolf Dietrich, Walter Tschugguel, Valery N. Bochkov, Ezzat M. Awad, Gerald Maurer, Kurt Huber, Johann Wojta

The estrogen metabolite 17-dihydroequilenin counteracts interleukin-1 induced expression of inflammatory mediators in human endothelial cells in vitro via NF-B pathway

In most studies showing cardio- and vasculoprotective effects of estrogens, 17-estradiol was used and little information on possible effects of different estrogen metabolites is yet available. We investigated whether particular estrogen metabolites are effective in counteracting inflammatory activation of human endothelium. Human endothelial cells were incubated with 17-dihydroequilenin, 17-dihydroequilenin, -8,9-dehydroestrone, estrone and 17-estradiol and stimulated with interleukin (IL)-1. The expression of IL-6, IL-8 and monocyte chemoattractant protein-1 (MCP-1) was determined. 17-dihydroequilenin and 17-estradiol at a concentration of 1 M reduced IL-1-induced up regulation of IL-6, IL-8 and MCP-1 close to control levels. When both compounds were used in combination an additive effect was observed. 17-dihydroequilenin and -8,9-dehydroestrone showed a similar anti-inflammatory effect only when used at 10 M whereas estrone had no effect. The effect of 17-dihydroequilenin on IL-1-induced production of IL-6, IL-8 and MCP-1 was reversed by the estrogen receptor antagonist ICI 182,780. 17-dihydroequilenin also inhibited IL-1-induced translocation of p50 and p65 to the nucleus of the cells. We have identified the estrogen metabolite 17-dihydroequilenin, as an inhibitor of inflammatory activation of human endothelial cells. Characterization of specific estrogens as shown in our study could provide the basis for tailored therapies, which might be able to achieve vasoprotection without adverse side effects.

Thrombosis and Haemostasis, Schattauer

Print ISSN: 0340-6245
Volume: 95, 01/2006
Pages: 107 - 116

Show full article (external site)

Show all available items of this journal